New drugs propel Bayer Healthcare's growth in Asia-Pacific
Published on Mar 21, 2014 3:34 PM
Bayer Healthcare - which has its Asia-Pacific headquaters in Singapore - is the region's fastest-growing drug company, new figures reveal.
Global health information service IMS Health found regional sales of its drugs grew by 15 per cent to $5.3 billion last year.
The German pharmaceutical giant is ranked ninth in the region in terms of sales and 14th worldwide with sales of $22 billion.
Bayer has launched several new drugs including Eylea, which fights macular degeneration - a major cause of blindness among the elderly. It went on sale in Singapore at the end of last year and was Bayer's best-ever drug launch in Australia, with sales topping $108 million within seven months of the product entering the market.
To continue reading, log in if you are a subscriber
If you are not a subscriber, you can get instant, unlimited access here